

pLVX-EF1α-DsRed-Monomer-N1

Catalog No(s). Amount Lot Number

631990 20 μl pLVX-EF1α-DsRed-Monomer-N1 vector (500 ng/μl) Specified on product label.

pLVX-EF1α-DsRed-Monomer-N1 Vector Information




Figure 1. pLVX-EF1α-DsRed-Monomer-N1 vector map.

Japan

+81.(0)77.543.6116

Figure 2. pLVX-EF1α-DsRed-Monomer-N1 multiple cloning site.

A Takara Bio Company

1290 Terra Bella Avenue, Mountain View, CA 94043, USA

U.S. Technical Support: tech@clontech.com

United States/Canada Asia Pacific Europe 800.662.2566 +1.650.919.7300 +33.(0)1.3904.6880 Late update: July 12, 2011

Location of Features

- 5' LTR (5' long terminal repeat): 1–635
- PBS (primer binding site): 636–653
- Ψ (packaging signal): 685–822
- RRE (Rev-response element): 1303–1536
- cPPT/CTS (central polypurine tract/central termination sequence): 2028–2151
- $P_{\text{EF1}\alpha}$ (human elongation factor 1 alpha promoter): 2185–3519
- MCS (multiple cloning site): 3560–3599
- DsRed-Monomer (human-codon-optimized): 3613–4290
- P_{PGK} (phosphoglycerate kinase promoter): 4310–4818
- Puro (puromycin resistance gene): 4839–5438
- WPRE (woodchuck hepatitis virus posttranscriptional regulatory element): 5452–6043
- 3' LTR (3' long terminal repeat): 6246–6882
- pUC origin of replication: 7351–8024 (complementary)
- Amp^r (ampicillin resistance gene; β-lactamase): 8169–9165 (complementary)

NOTICE TO PURCHASER:

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, in vitro diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without prior written approval of Clontech Laboratories, Inc.

Your use of this product is also subject to compliance with the licensing requirements listed below and described on the product's web page at http://www.clontech.com. It is your responsibility to review, understand and adhere to any restrictions imposed by these statements.

Last update: July 12, 2011 Page 2 of 2